Teva Pharmaceutical Industries Ltd.'s new management expects to achieve organic, profitable growth by globalizing key operating functions to reshape its cost structure while regionally tailoring its product offerings and using business development to amass capabilities incrementally.

In a preview of its strategy with BioCentury, the company disclosed it is refocusing R&D on key growth drivers in complex and combination generics called new therapeutic entities (NTEs), and branded specialty drugs for CNS and respiratory diseases (see BioCentury, Dec. 10).